
## **WEST Search History**

DATE: Friday, August 01, 2003

Set Name side by side	Query	Hit Count	Set Name result set
DB = US	PT; PLUR=YES; OP=ADJ		
L6	L1 and protease and herpes.clm.	0	L6
L5	L1 and protease and CMV.clm.	0	L5
L4	L1 and protease and CMV	29	L4
L3	L1 and protease	66	L3
L2	preventing apoptosis.clm.	. 8	L2
L1	preventing apoptosis	90	L1

END OF SEARCH HISTORY



L2: Entry 1 of 8

File: USPT

Feb 25, 2003

US-PAT-NO: 6524821

DOCUMENT-IDENTIFIER: US 6524821 B1

TITLE: Anti-apoptotic compositions comprising the R1 subunit of herpes simplex virus

ribonucleotide reductase or its N-terminal portion; and uses thereof

DATE-ISSUED: February 25, 2003

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Langelier; Yves Montreal CA Massie; Bernard Montreal CA

US-CL-CURRENT: 435/69.1; 435/183, 435/235.1, 435/320.1, 530/350,

CLAIMS:

## What is claimed is:

- 1. A method for preventing apoptosis in vitro, induced in a cell by an apoptotic component other than Herpes simplex virus ribonucleotide reductase without the N-terminal 357 amino acids thereof, which comprises the step of submitting said cell to an anti-apoptotic treatment with an anti-apoptotic agent comprising R1 subunit of Herpes simplex virus ribonucleotide reductase enzyme or a nucleic acid encoding said enzyme.
- 2. A method as defined in claim 1, which further comprises the step of co-administering another anti-apoptotic agent.
- 3. A method as defined in claim 1, wherein said anti-apoptotic treatment comprises achieving in said cell a concentration of about 0.005% R1 subunit of Herpes simplex virus ribonucleotide reductase enzyme with regard to the amount of total cellular proteins.
- 4. A method as defined in claim 1, wherein said apoptotic component involves TNF-.alpha., Fas or Caspase 8 activation in said cell.